Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep 2;10(17):3980.
doi: 10.3390/jcm10173980.

Genetics Variants in the Epoxygenase Pathway of Arachidonic Metabolism Are Associated with Eicosanoids Levels and the Risk of Diabetic Nephropathy

Sonia Mota-Zamorano  1 , Nicolás R Robles  2 , Luz M González  1 , José M Valdivielso  3 , Juan Lopez-Gomez  4 , Bárbara Cancho  2 , Guadalupe García-Pino  5 , Guillermo Gervasini  1
Affiliations

Genetics Variants in the Epoxygenase Pathway of Arachidonic Metabolism Are Associated with Eicosanoids Levels and the Risk of Diabetic Nephropathy

Sonia Mota-Zamorano et al. J Clin Med. .

Abstract

Genes in the epoxygenase pathway of arachidonic acid metabolism leading to vasoactive eicosanoids, mainly 20-hydroxyeicosatetraenoic (20-HETE) and epoxyeicosatrienoic (EETs) acids, have been related to glucose-induced renal damage in preclinical reports. We genotyped 1088 diabetic kidney disease (DKD) patients and controls for seven polymorphisms in five genes (CYP2C8, CYP2J2, CYP4F2, CYP4A11, and EPHX2) along this metabolic route and evaluated their effect on DKD risk, clinical outcomes, and the plasma/urine levels of eicosanoids measured by LC/MS/MS and immunoenzymatic assays. The CYP4F2 433M variant allele was associated with lower incidence of DKD (OR = 0.65 (0.48-0.90), p = 0.008), whilst the CYP2C8*3/*3 genotype was related to increased risk (OR = 3.21 (1.05-9.87), p = 0.036). Patients carrying the 433M allele also showed lower eGFR [median and interquartile range vs. wildtype carriers: 30.8 (19.8) and 33.0 (23.2) mL/min/1.73 m2, p = 0.037). Finally, the 433VM/MM variant genotypes were associated with lower urinary levels of 20-HETE compared with 433VV (3.14 (0.86) vs. 8.45 (3.69) ng/mg Creatinine, p = 0.024). Our results indicate that the CYP4F2 V433M polymorphism, by decreasing 20-HETE levels, may play an important role in DKD.

Keywords: CYP4F2; chronic kidney disease; diabetes mellitus; diabetic kidney disease.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The sponsors had no role in the design, execution, interpretation, or writing of the study.

References

    1. Foreman K.J., Marquez N., Dolgert A., Fukutaki K., Fullman N., McGaughey M., Pletcher M.A., Smith A.E., Tang K., Yuan C.-W., et al. Forecasting life expectancy, years of life lost, and all-Cause and cause-Specific mortality for 250 causes of death: Reference and alternative scenarios for 2016-40 for 195 countries and territories. Lancet. 2018;392:2052–2090. doi: 10.1016/S0140-6736(18)31694-5. - DOI - PMC - PubMed
    1. Pugliese G., Penno G., Natali A., Barutta F., Di Paolo S., Reboldi G., Gesualdo L., De Nicola L. Diabetic kidney disease: New clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on “The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function”. J. Nephrol. 2020;33:9–35. doi: 10.1007/s40620-019-00650-x. - DOI - PMC - PubMed
    1. Warren A., Knudsen S.T., Cooper M.E. Diabetic nephropathy: An insight into molecular mechanisms and emerging therapies. Expert Opin. Ther. Targets. 2019;23:579–591. doi: 10.1080/14728222.2019.1624721. - DOI - PubMed
    1. Furuichi K., Shimizu M., Hara A., Toyama T., Wada T. Diabetic Nephropathy: A Comparison of the Clinical and Pathological Features between the CKD Risk Classification and the Classification of Diabetic Nephropathy 2014 in Japan. Intern. Med. 2018;57:3345–3350. doi: 10.2169/internalmedicine.1132-18. - DOI - PMC - PubMed
    1. Ahmad J. Management of diabetic nephropathy: Recent progress and future perspective. Diabetes Metab. Syndr. Clin. Res. Rev. 2015;9:343–358. doi: 10.1016/j.dsx.2015.02.008. - DOI - PubMed